Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1654 1672
This examiner grants 60% of resolved cases
Marianne P Allen has resolved 1002 cases in Tech Center 1600 and Art Unit 1647. The allowance rate is 60.0 percent, which is a solid success rate for applicants. This 60.0 percent rate indicates that the majority of the 1002 cases result in a patent grant. The data reflects a stable prosecution environment.
The interview lift is 18.0 percent, indicating that interviews are a helpful tool for moving cases forward. The median days to allowance is 1055, which is a standard duration for reaching a grant. Practitioners should expect a 1055-day timeline for successful applications. The 18.0 percent lift can be used to resolve outstanding issues and secure the 60.0 percent allowance rate. These figures suggest that the examiner is consistent and that direct communication provides a modest but reliable benefit during the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 18612561 | Modulation of Heparin-Binding Epidermal Growth Factor Activity for Tympanic Membrane Healing | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17916664 | AFFINITY MATURED ANTI-LAP ANTIBODIES AND USES THEREOF | Non-Final OA | Merck Sharp & Dohme LLC |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18312194 | NANOPARTICLE VACCINES AND USES THEREOF FOR PROPHYLAXIS AND TREATMENT OF ATHEROSCLEROSIS USING PEPTIDE 210 AS AN ANTIGEN | Non-Final OA | University of Southern California |
| 18059180 | SYSTEM AND METHODS FOR INCREASING SYNTHESIZED PROTEIN STABILITY | Non-Final OA | Board of Regents, The University of Texas System |
| 17408937 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | Final Rejection | Sanofi |
| 17782717 | PROTEIN BLOCKING ASSEMBLY AND METHODS OF MAKING AND USING | Non-Final OA | The Curators of the University of Missouri |
| 18262548 | ELECTROTRANSFER METHODS FOR TREATING TUMORS | Final Rejection | UNIVERSITY OF SOUTH FLORIDA |
| 17242793 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS | Final Rejection | UMC Utrecht Holding B.V. |
| 18289934 | Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition | Non-Final OA | Tokyo University of Science Foundation |
| 18044158 | MATERIALS AND METHODS TO REDUCE PROTEIN AGGREGATION | Non-Final OA | AMGEN INC. |
| 17775257 | METHOD OF TREATING OR AMELIORATING CUSHING'S SYNDROME USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) | Final Rejection | AMGEN INC. |
| 18154020 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Final Rejection | Janssen Pharmaceutica NV |
| 17924613 | ST2 ANTIGEN BINDING PROTEIN | Final Rejection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Final Rejection | GENZYME CORPORATION |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | Non-Final OA | MedImmune, LLC |
| 18694365 | ANTI-KLB ANTIBODIES AND USES | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | Non-Final OA | Seagen Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy